May 21, 2021 -- Therapeutic Solutions International announced new data and a patent filing demonstrating that lithium carbonate augments the scar-inhibiting activity of its JadiCell universal donor stem cell therapy.
In double-blind, placebo-controlled clinical trial, JadiCell was successful at substantially improving survival in end-stage patients with acute lung failure associated with COVID-19. The treatment was associated with significantly improved patient survival, serious adverse event-free survival, and time to recovery.
The company plans to initiate a phase III pivotal registration trial and seek marketing approval for use of JadiCell in acute respiratory distress syndrome and other lung diseases.
Copyright © 2021 scienceboard.net